AHA shares proposals to lower Medicare drug prices with Congress
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program.
Related News Articles
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Perspective
Congress returns to Washington, D.C., this week facing a long list of things to do, including several that will impact hospitals’ ability to provide access to…
Headline
The House Appropriations Committee today released the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services, Education,…
Headline
The Department of Health and Human Services today announced prescription drug reforms that will become effective Oct. 1 originating from the Health Data,…
Headline
The AHA Aug. 11 urged the Centers for Medicare & Medicaid Services to prioritize payments to hospitals from the Rural Health Transformation Program. The…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…